Reduction of Adverse Drug Events and Readmissions

Eligibility Criteria

• 1. Male or female patients of 25 years of age or older who are able to give their written Informed Consent to participate in a Clinical Study based on voluntary agreement with a thorough explanation of the patient's participation will be provided to them.
• 2. Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 120 days ("index PGx test assessment");
• 3. Patient was receiving at least one medication known to be associated with allelic variation at the time of the ("index PGx test assessment"), including over-the- counter medications;
• 4. Patient has a history of at least one TDAE over the 24-month period preceding the PGx test assessment, or has experienced inadequate efficacy from a target drug.
• 1. Patient is currently hospitalized;
• 2. Patient's medical and medication history is unavailable over the 120-day period preceding the PGx test assessment;
• 3. Patient is unable to provide an accurate history due to mental Incapacity;
• 4. Patient is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Study.